Tempus AI, Inc. (NASDAQ:TEM) Receives $56.36 Average Price Target from Brokerages

Tempus AI, Inc. (NASDAQ:TEM) has received an average rating of “Moderate Buy” from the twelve analysts that are presently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $56.36.

Several analysts recently weighed in on the stock. Piper Sandler reiterated a “neutral” rating and issued a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and boosted their price target for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Loop Capital lowered their price objective on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a report on Tuesday, January 14th. Wolfe Research initiated coverage on Tempus AI in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price on the stock. Finally, Guggenheim assumed coverage on Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 target price for the company.

Insiders Place Their Bets

In other Tempus AI news, major shareholder Bradley A. Keywell sold 265,000 shares of the business’s stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $35.10, for a total value of $9,301,500.00. Following the completion of the transaction, the insider now owns 15,218,365 shares of the company’s stock, valued at approximately $534,164,611.50. The trade was a 1.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David R. Epstein sold 620 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total transaction of $25,922.20. Following the sale, the director now directly owns 27,894 shares in the company, valued at approximately $1,166,248.14. The trade was a 2.17 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,037,702 shares of company stock valued at $89,449,651.

Institutional Trading of Tempus AI

Large investors have recently modified their holdings of the company. Kovitz Investment Group Partners LLC bought a new stake in shares of Tempus AI during the 3rd quarter valued at about $1,367,000. Sumitomo Mitsui Trust Group Inc. grew its position in Tempus AI by 1,591.2% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after buying an additional 1,145,698 shares during the period. Captrust Financial Advisors purchased a new stake in Tempus AI during the third quarter valued at approximately $2,726,000. Sigma Planning Corp bought a new position in Tempus AI in the third quarter worth approximately $1,323,000. Finally, Dakota Wealth Management purchased a new position in shares of Tempus AI during the 3rd quarter worth $1,185,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Stock Performance

NASDAQ TEM opened at $57.39 on Friday. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. Tempus AI has a fifty-two week low of $22.89 and a fifty-two week high of $79.49. The stock has a 50 day simple moving average of $44.18 and a two-hundred day simple moving average of $48.18.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.